Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilan Bruchim

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
Journal of Comparative Effectiveness Research|December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancerWhitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III TrialAntonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
Journal of Comparative Effectiveness Research|December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancerWhitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III TrialAntonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Pageof 9